Editor, Author at WSTPR

NeOnc’s NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

August 12, 2026

Phase 2a results showed 48.9% six-month progression-free survival versus a 20% historical benchmark, with median overall survival reaching approximately 26 months Houston, Texas (www.wallstreet-pr.com) –

VENU Holding Corporation (NYSE: VENU): Napkin Math, Why It’s a Smarter 3-Year Play Than Nuclear, Robotics, Minerals, or AI

November 7, 2025

Senior Financial Editor Hey investors, Here’s a quick, back-of-the-envelope breakdown on why VENU Holdings inc. (NYSE:VENU), the upscale live music venue builder, could deliver explosive